REDWOOD CITY, CA -- (BUSINESS WIRE) -- Proteus Digital Health, Inc., announced that the company has completed a second closing of its Series F financing, raising $62.5 million in total. New corporate investor Oracle joins Otsuka, Novartis, Sino Portfolio and others in this funding round.
Proteus Digital Health is working to create a new category of products, services and data systems that have the potential to significantly improve the effectiveness of existing pharmaceutical treatments, leading to fundamentally new care paradigms. Called Digital Medicines, these new pharmaceuticals will contain a tiny sensor that can communicate, via a digital health feedback system, vital information about an individual's medication-taking behavior and how their body is responding.
"The commitment of our strategic partners helps us to accelerate our mission," said Andrew Thompson, CEO of Proteus. "By embedding Proteus technology into established, market leading products & services we are changing healthcare and empowering patients, physicians and researchers with digital technology."
About Proteus Digital Health
Proteus Digital Health is pioneering a new category of products, services and data systems based on ingestible sensing. Its core technology—the digital health feedback system—provides an unprecedented view into an individual's personal health choices and physiologic response, allowing patients to better manage their health and more effectively collaborate with caregivers and clinicians while enabling new information-based business models. Proteus has received a CE mark in Europe and FDA market clearance in the U.S. for its wearable and ingestible sensor devices. Headquartered in Redwood City, CA, Proteus is privately held and funded by Carlyle, Essex Woodlands, Kaiser Permanente, Medtronic, Novartis, Otsuka, Oracle, ON Semiconductor and other investors.